JP2023546493A5 - - Google Patents

Info

Publication number
JP2023546493A5
JP2023546493A5 JP2023524898A JP2023524898A JP2023546493A5 JP 2023546493 A5 JP2023546493 A5 JP 2023546493A5 JP 2023524898 A JP2023524898 A JP 2023524898A JP 2023524898 A JP2023524898 A JP 2023524898A JP 2023546493 A5 JP2023546493 A5 JP 2023546493A5
Authority
JP
Japan
Prior art keywords
antibody
drug conjugate
linker
seq
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023524898A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546493A (ja
JP7789396B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/079560 external-priority patent/WO2022084560A1/en
Publication of JP2023546493A publication Critical patent/JP2023546493A/ja
Publication of JP2023546493A5 publication Critical patent/JP2023546493A5/ja
Priority to JP2025195595A priority Critical patent/JP2026020207A/ja
Application granted granted Critical
Publication of JP7789396B2 publication Critical patent/JP7789396B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023524898A 2020-10-25 2021-10-25 抗体-リンカーコンジュゲートを生成するための手段および方法 Active JP7789396B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025195595A JP2026020207A (ja) 2020-10-25 2025-11-14 抗体-リンカーコンジュゲートを生成するための手段および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20020492 2020-10-25
EP20020492.3 2020-10-25
EP20203887 2020-10-26
EP20203887.3 2020-10-26
PCT/EP2021/079560 WO2022084560A1 (en) 2020-10-25 2021-10-25 Means and methods for producing antibody-linker conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025195595A Division JP2026020207A (ja) 2020-10-25 2025-11-14 抗体-リンカーコンジュゲートを生成するための手段および方法

Publications (3)

Publication Number Publication Date
JP2023546493A JP2023546493A (ja) 2023-11-02
JP2023546493A5 true JP2023546493A5 (cg-RX-API-DMAC10.html) 2025-10-22
JP7789396B2 JP7789396B2 (ja) 2025-12-22

Family

ID=78463477

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023524898A Active JP7789396B2 (ja) 2020-10-25 2021-10-25 抗体-リンカーコンジュゲートを生成するための手段および方法
JP2025195595A Pending JP2026020207A (ja) 2020-10-25 2025-11-14 抗体-リンカーコンジュゲートを生成するための手段および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025195595A Pending JP2026020207A (ja) 2020-10-25 2025-11-14 抗体-リンカーコンジュゲートを生成するための手段および方法

Country Status (12)

Country Link
US (3) US12076412B2 (cg-RX-API-DMAC10.html)
EP (1) EP4232095A1 (cg-RX-API-DMAC10.html)
JP (2) JP7789396B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230096052A (cg-RX-API-DMAC10.html)
AU (1) AU2021366341A1 (cg-RX-API-DMAC10.html)
CA (1) CA3196218A1 (cg-RX-API-DMAC10.html)
CL (1) CL2023001101A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023005374A2 (cg-RX-API-DMAC10.html)
IL (1) IL302017A (cg-RX-API-DMAC10.html)
MX (1) MX2023004606A (cg-RX-API-DMAC10.html)
PE (1) PE20231512A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022084560A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018337671B2 (en) 2017-09-19 2021-03-04 Paul Scherrer Institut Transglutaminase conjugation method and linker
EP4673182A1 (en) * 2023-06-04 2026-01-07 Araris Biotech AG Dual payload antibody drug conjugates for the treatment of cancer
CN122249239A (zh) * 2024-02-08 2026-06-19 苏州佰睿壹生物技术有限公司 抗体、抗体-药物偶联物及其制备方法
WO2025184499A1 (en) * 2024-03-01 2025-09-04 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2025192692A1 (ja) * 2024-03-14 2025-09-18 東レ株式会社 癌の治療及び/又は予防用医薬組成物
WO2026093993A1 (en) 2024-11-01 2026-05-07 Janssen Biotech, Inc. Methods and systems for enhanced multispecific metabolic and cellular targeting
WO2026150353A2 (en) 2025-01-11 2026-07-16 Biohaven Therapeutics Ltd. Antibody-drug conjugates for delivering cytotoxic agents

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
FI990180A7 (fi) 1996-08-12 1999-03-08 Celgene Corp Uusia immunoterapeuttisia aineita ja niiden käyttö sytokiini-tasojen pienentämiseksi
US5969516A (en) 1997-07-25 1999-10-19 Ntc, Inc. Electrical circuit interrupter device locator
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
EP1499885B1 (en) 2001-08-01 2009-10-21 Cellomics, Inc. Novel fusion proteins and assays for molecular binding
US6660510B2 (en) 2001-12-17 2003-12-09 Food Industry Research And Development Transglutaminase gene of Streptoverticillium ladakanum and the transglutaminase encoded therefrom
JP2005522514A (ja) 2002-04-10 2005-07-28 ジェネンテック・インコーポレーテッド 抗her2抗体改変体
WO2004043493A1 (en) 2002-11-14 2004-05-27 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
US7955814B2 (en) 2003-01-17 2011-06-07 Danisco A/S Method
EP2290085B1 (en) 2003-01-17 2017-12-13 DuPont Nutrition Biosciences ApS Method for the in situ production of an emulsifier in a foodstuff
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
EP2123756B1 (en) 2007-02-15 2014-06-04 Ajinomoto Co., Inc. Transglutaminase having disulfide bond introduced therein
WO2008102007A1 (en) 2007-02-22 2008-08-28 Novo Nordisk Health Care Ag Transglutaminase variants with improved specificity
PT2474557E (pt) 2007-07-16 2014-12-03 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
EP2197443A4 (en) 2007-09-26 2014-01-01 Gemin X Pharmaceuticals Canada Inc COMPOSITIONS AND METHOD FOR LEADING NAD + MIRRORS USING A NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE HEMMER
DK2657253T3 (en) 2008-01-31 2017-10-09 Genentech Inc Anti-CD79b antibodies and immune conjugates and methods of use
MX2011010469A (es) 2009-04-08 2012-03-14 Deutsches Krebsforsch Radicales de enlace al objetivo, armados con amatoxina para el tratamiento del cancer.
EP3192529B1 (en) 2009-04-08 2020-03-25 Faulstich, Heinz, Dr. Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy
EP2963111A1 (en) 2009-12-22 2016-01-06 Lifebond Ltd Modification of enzymatic crosslinkers for controlling properties of crosslinked matrices
WO2011119484A1 (en) 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
AR082886A1 (es) 2010-09-03 2013-01-16 Forma Therapeutics Inc Compuestos y composiciones farmaceuticas que los contienen
ES2874306T3 (es) 2010-09-29 2021-11-04 Agensys Inc Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12
ES2402254T3 (es) 2010-09-30 2013-04-30 Heidelberg Pharma Ag Conjugados de amatoxinas con ligadores mejorados
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
EP2497499A1 (en) 2011-03-10 2012-09-12 Heidelberg Pharma GmbH Amatoxin-conjugates with improved linkages
EP2771349B1 (en) 2011-09-16 2020-02-26 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
WO2013049830A2 (en) 2011-09-30 2013-04-04 The Washington University Tip-1 and grp-78 binding peptides and method of identifying peptide receptors
CA2858806A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
EP2872894B1 (en) 2012-07-13 2019-04-17 Innate Pharma Screening of conjugated antibodies
EP2774624A1 (en) 2013-03-04 2014-09-10 Heidelberg Pharma GmbH Amatoxin derivatives
EP2777714A1 (en) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
US10611824B2 (en) 2013-03-15 2020-04-07 Innate Pharma Solid phase TGase-mediated conjugation of antibodies
KR20160042871A (ko) 2013-06-21 2016-04-20 이나뜨 파르마, 에스.아. 폴리펩티드의 효소적 콘쥬게이션
US10195289B2 (en) 2013-07-31 2019-02-05 Rinat Neuroscience Corp. Engineered polypeptide conjugates using transglutaminase
WO2015054060A1 (en) 2013-10-09 2015-04-16 Eli Lilly And Company Novel pyridyloxyacetyl tetrahydroisoquinoline compounds useful as nampt inhibitors
JP6865584B2 (ja) 2013-12-23 2021-04-28 コヴァラブ 化合物の共有結合性コンジュゲーションのためのmTG基質
KR20190072663A (ko) 2014-04-25 2019-06-25 리나트 뉴로사이언스 코프. 약물이 고도로 로딩된 항체-약물 접합체
CA2951887A1 (en) 2014-06-12 2015-12-17 Cspc Dophen Corporation Homogenous antibody drug conjugates via enzymatic methods
HUE049325T2 (hu) 2014-08-28 2020-09-28 Pfizer Stabilitás modulátor linker antitest-hatóanyag konjugátumokhoz történõ alkalmazásra
ES2871624T3 (es) 2014-12-19 2021-10-29 Hoffmann La Roche Transglutaminasas microbianas, sustratos para las mismas y procedimientos para el uso de las mismas
US20180028682A1 (en) 2015-02-09 2018-02-01 Nbe Therapeutics Ag Maytansine-drug conjugates of her-2 specific binding proteins generated by site specific sortase-enzyme mediated conjugation
ES2736106T3 (es) 2015-03-10 2019-12-26 Bristol Myers Squibb Co Anticuerpos que se pueden conjugar mediante la transglutaminasa y conjugados producidos a partir de ellos
EP3069734A1 (en) 2015-03-17 2016-09-21 Exiris S.r.l. Cryptophycin-based antibody-drug conjugates with novel self-immolative linkers
MX2017017138A (es) 2015-06-23 2018-04-30 Bayer Pharma AG Conjugados homogeneos especificos de sitio con inhibidores de ksp.
WO2017025179A1 (en) 2015-08-07 2017-02-16 Merck Patent Gmbh A transglutamine tag for efficient site-specific bioconjugation
US10689458B2 (en) 2015-11-30 2020-06-23 Pfizer Inc. Site specific HER2 antibody drug conjugates
EP4032902A1 (en) 2015-12-18 2022-07-27 Eisai R&D Management Co., Ltd. C-terminal lysine conjugated immunoglobulins
EP3272864A1 (en) 2016-07-20 2018-01-24 Paul Scherrer Institut Solid-phase immobilization of microbial transglutaminase mtg on microbeads for protein conjugation
US10906957B2 (en) 2016-09-27 2021-02-02 Epicentrx, Inc. Immunomodulatory fusion proteins
KR20230008269A (ko) 2017-08-07 2023-01-13 엔비이-테라퓨틱스 아게 생체 내 내성이 높은 항체 약물 결합체
AU2018337671B2 (en) 2017-09-19 2021-03-04 Paul Scherrer Institut Transglutaminase conjugation method and linker
WO2019082020A1 (en) 2017-10-27 2019-05-02 Pfizer Inc. ANTIBODIES AND CONJUGATES CD123-SPECIFIC ANTIBODIES AND USES THEREOF
CN113613679A (zh) * 2019-03-19 2021-11-05 保罗·谢勒学院 基于甘氨酸的接头的转谷氨酰胺酶缀合方法
EP4213886A1 (en) 2020-09-18 2023-07-26 Araris Biotech AG Transglutaminase conjugation method with amino acid-based linkers

Similar Documents

Publication Publication Date Title
JP2025016545A5 (cg-RX-API-DMAC10.html)
Sau et al. Advances in antibody–drug conjugates: A new era of targeted cancer therapy
Trail et al. Monoclonal antibody drug immunoconjugates for targeted treatment of cancer
JP2022525704A5 (cg-RX-API-DMAC10.html)
US20230173093A1 (en) Charge variant linkers
Teicher et al. Antibody conjugate therapeutics: challenges and potential
CN106456794B (zh) 接头药物与抗体的位点特异性缀合以及所得adc
JP2022530524A5 (cg-RX-API-DMAC10.html)
US10029014B2 (en) Synthesis of novel asymmetric bow-tie PAMAM dendrimer-based conjugates for tumor-targeting drug delivery
KR20140139480A (ko) 항체-약물 접합체 및 관련 화합물, 조성물, 및 방법
JP2012522513A5 (cg-RX-API-DMAC10.html)
JP2022547434A (ja) 標的化デンドリマー複合体
JP6486316B2 (ja) 抗体−薬物複合体(adc)およびそれを形成するための方法
FI3930847T3 (fi) Korkea-affiinisia anti-MERTK-vasta-aineita ja niiden käyttöjä
JP2025183203A5 (cg-RX-API-DMAC10.html)
JP2022547434A5 (cg-RX-API-DMAC10.html)
JP2025506768A5 (cg-RX-API-DMAC10.html)
TW201925229A (zh) 經捲曲螺旋遮蔽之二價抗體
CN109963620A (zh) 细胞靶向缀合物
JP2024539989A5 (cg-RX-API-DMAC10.html)
TW201905000A (zh) 含有抗globo h抗體之抗體-藥物共軛物及其用途
JP2023542910A5 (cg-RX-API-DMAC10.html)
JP2026501556A (ja) 抗体薬物複合体
TW202509083A (zh) 抗體及其抗體-藥物偶聯物
JPWO2021251459A5 (cg-RX-API-DMAC10.html)